APEA Psychiatric-Mental Health
Nurse Practitioner PMHNP Exam
ACTUAL EXAM 2026/2027 | PMHNP
Certification | Verified Q&A | Pass
Guaranteed - A+ Graded
Domain I: Scientific Foundation (15 questions)
Q1: According to the monoamine hypothesis of depression, which neurotransmitter is primarily
associated with the regulation of mood, sleep, and appetite?
A. Dopamine only
B. Serotonin and norepinephrine [CORRECT]
C. GABA only
D. Glutamate only
Correct Answer: B
Rationale: The monoamine hypothesis implicates serotonin and norepinephrine in depression
pathophysiology. Dopamine (A) is involved in reward and motivation but not the primary monoamine in
this hypothesis. GABA (C) is the primary inhibitory neurotransmitter. Glutamate (D) is involved in the
glutamate hypothesis targeted by ketamine, not the monoamine hypothesis.
Q2: Which dopamine pathway is associated with the negative symptoms of schizophrenia when
underactive?
A. Nigrostriatal pathway
B. Mesolimbic pathway
C. Mesocortical pathway [CORRECT]
,D. Tuberoinfundibular pathway
Correct Answer: C
Rationale: The mesocortical pathway (prefrontal cortex) is associated with cognition and negative
symptoms when hypodopaminergic. The nigrostriatal pathway (A) is involved in movement (EPS when
blocked). The mesolimbic pathway (B) is hyperdopaminergic in positive symptoms. The
tuberoinfundibular pathway (D) regulates prolactin.
Q3: The HPA axis hyperactivity observed in depression and PTSD is characterized by which hormonal
pattern?
A. Decreased cortisol and increased CRH
B. Increased cortisol and blunted negative feedback [CORRECT]
C. Normal cortisol and decreased ACTH
D. Decreased cortisol and decreased CRH
Correct Answer: B
Rationale: Depression and PTSD show HPA axis hyperactivity with elevated cortisol and impaired
negative feedback (dexamethasone nonsuppression). Decreased cortisol (A, D) is incorrect. Normal
cortisol (C) does not reflect HPA axis dysregulation.
Q4: Which CYP450 enzyme is responsible for metabolizing approximately 50% of psychotropic
medications?
A. CYP1A2
B. CYP2C19
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 metabolizes approximately 50% of all medications, including many psychotropics
(benzodiazepines, atypical antipsychotics, carbamazepine). CYP1A2 (A) metabolizes clozapine and
olanzapine (smoking induces). CYP2C19 (B) metabolizes diazepam, citalopram. CYP2D6 (C) metabolizes
many antidepressants and antipsychotics (fluoxetine, paroxetine, risperidone).
,Q5: Which genetic polymorphism is associated with ultra-rapid metabolism of CYP2D6 substrates,
potentially leading to therapeutic failure?
A. Poor metabolizer status
B. Intermediate metabolizer status
C. Extensive metabolizer status
D. Ultra-rapid metabolizer status [CORRECT]
Correct Answer: D
Rationale: Ultra-rapid metabolizers have multiple copies of the CYP2D6 gene, leading to rapid drug
clearance and subtherapeutic levels. Poor metabolizers (A) have toxic accumulation. Intermediate (B)
and extensive (C) metabolizers have normal or slightly reduced metabolism.
Q6: (Select all that apply): Which factors can contribute to treatment-resistant depression? Select all
that apply.
A. Undiagnosed bipolar disorder [CORRECT]
B. Comorbid substance use disorder [CORRECT]
C. Inadequate trial duration or dosage [CORRECT]
D. Presence of psychotic features [CORRECT]
E. Use of evidence-based psychotherapy
Correct Answer Set: A, B, C, D
Rationale: Treatment resistance may be due to misdiagnosed bipolar (A), substance use (B), inadequate
treatment (C), or psychotic features requiring different treatment (D). Evidence-based psychotherapy (E)
improves outcomes, not causes resistance.
Q7: The glutamate hypothesis of depression has led to the development of which rapid-acting
antidepressant?
A. Fluoxetine
B. Sertraline
, C. Ketamine [CORRECT]
D. Venlafaxine
Correct Answer: C
Rationale: Ketamine is an NMDA receptor antagonist that modulates glutamate neurotransmission,
producing rapid antidepressant effects (hours to days). SSRIs (A, B) and SNRIs (D) work on monoamines
with delayed onset (weeks).
Q8: Which neurotransmitter is the primary target of benzodiazepines?
A. Serotonin
B. Dopamine
C. GABA [CORRECT]
D. Norepinephrine
Correct Answer: C
Rationale: Benzodiazepines enhance GABA-A receptor function, increasing chloride influx and neuronal
inhibition. They do not primarily target serotonin (A), dopamine (B), or norepinephrine (D).
Q9: Epigenetic modifications in psychiatry refer to:
A. Changes in DNA sequence
B. Changes in gene expression without altering DNA sequence [CORRECT]
C. Chromosomal abnormalities
D. Mitochondrial DNA mutations
Correct Answer: B
Rationale: Epigenetics involves changes in gene expression (methylation, histone modification) without
DNA sequence changes. DNA sequence changes (A), chromosomal abnormalities (C), and mitochondrial
mutations (D) are genetic, not epigenetic.
Q10: Which evidence-based practice model emphasizes the integration of clinical expertise, patient
values, and best research evidence?
Nurse Practitioner PMHNP Exam
ACTUAL EXAM 2026/2027 | PMHNP
Certification | Verified Q&A | Pass
Guaranteed - A+ Graded
Domain I: Scientific Foundation (15 questions)
Q1: According to the monoamine hypothesis of depression, which neurotransmitter is primarily
associated with the regulation of mood, sleep, and appetite?
A. Dopamine only
B. Serotonin and norepinephrine [CORRECT]
C. GABA only
D. Glutamate only
Correct Answer: B
Rationale: The monoamine hypothesis implicates serotonin and norepinephrine in depression
pathophysiology. Dopamine (A) is involved in reward and motivation but not the primary monoamine in
this hypothesis. GABA (C) is the primary inhibitory neurotransmitter. Glutamate (D) is involved in the
glutamate hypothesis targeted by ketamine, not the monoamine hypothesis.
Q2: Which dopamine pathway is associated with the negative symptoms of schizophrenia when
underactive?
A. Nigrostriatal pathway
B. Mesolimbic pathway
C. Mesocortical pathway [CORRECT]
,D. Tuberoinfundibular pathway
Correct Answer: C
Rationale: The mesocortical pathway (prefrontal cortex) is associated with cognition and negative
symptoms when hypodopaminergic. The nigrostriatal pathway (A) is involved in movement (EPS when
blocked). The mesolimbic pathway (B) is hyperdopaminergic in positive symptoms. The
tuberoinfundibular pathway (D) regulates prolactin.
Q3: The HPA axis hyperactivity observed in depression and PTSD is characterized by which hormonal
pattern?
A. Decreased cortisol and increased CRH
B. Increased cortisol and blunted negative feedback [CORRECT]
C. Normal cortisol and decreased ACTH
D. Decreased cortisol and decreased CRH
Correct Answer: B
Rationale: Depression and PTSD show HPA axis hyperactivity with elevated cortisol and impaired
negative feedback (dexamethasone nonsuppression). Decreased cortisol (A, D) is incorrect. Normal
cortisol (C) does not reflect HPA axis dysregulation.
Q4: Which CYP450 enzyme is responsible for metabolizing approximately 50% of psychotropic
medications?
A. CYP1A2
B. CYP2C19
C. CYP2D6
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 metabolizes approximately 50% of all medications, including many psychotropics
(benzodiazepines, atypical antipsychotics, carbamazepine). CYP1A2 (A) metabolizes clozapine and
olanzapine (smoking induces). CYP2C19 (B) metabolizes diazepam, citalopram. CYP2D6 (C) metabolizes
many antidepressants and antipsychotics (fluoxetine, paroxetine, risperidone).
,Q5: Which genetic polymorphism is associated with ultra-rapid metabolism of CYP2D6 substrates,
potentially leading to therapeutic failure?
A. Poor metabolizer status
B. Intermediate metabolizer status
C. Extensive metabolizer status
D. Ultra-rapid metabolizer status [CORRECT]
Correct Answer: D
Rationale: Ultra-rapid metabolizers have multiple copies of the CYP2D6 gene, leading to rapid drug
clearance and subtherapeutic levels. Poor metabolizers (A) have toxic accumulation. Intermediate (B)
and extensive (C) metabolizers have normal or slightly reduced metabolism.
Q6: (Select all that apply): Which factors can contribute to treatment-resistant depression? Select all
that apply.
A. Undiagnosed bipolar disorder [CORRECT]
B. Comorbid substance use disorder [CORRECT]
C. Inadequate trial duration or dosage [CORRECT]
D. Presence of psychotic features [CORRECT]
E. Use of evidence-based psychotherapy
Correct Answer Set: A, B, C, D
Rationale: Treatment resistance may be due to misdiagnosed bipolar (A), substance use (B), inadequate
treatment (C), or psychotic features requiring different treatment (D). Evidence-based psychotherapy (E)
improves outcomes, not causes resistance.
Q7: The glutamate hypothesis of depression has led to the development of which rapid-acting
antidepressant?
A. Fluoxetine
B. Sertraline
, C. Ketamine [CORRECT]
D. Venlafaxine
Correct Answer: C
Rationale: Ketamine is an NMDA receptor antagonist that modulates glutamate neurotransmission,
producing rapid antidepressant effects (hours to days). SSRIs (A, B) and SNRIs (D) work on monoamines
with delayed onset (weeks).
Q8: Which neurotransmitter is the primary target of benzodiazepines?
A. Serotonin
B. Dopamine
C. GABA [CORRECT]
D. Norepinephrine
Correct Answer: C
Rationale: Benzodiazepines enhance GABA-A receptor function, increasing chloride influx and neuronal
inhibition. They do not primarily target serotonin (A), dopamine (B), or norepinephrine (D).
Q9: Epigenetic modifications in psychiatry refer to:
A. Changes in DNA sequence
B. Changes in gene expression without altering DNA sequence [CORRECT]
C. Chromosomal abnormalities
D. Mitochondrial DNA mutations
Correct Answer: B
Rationale: Epigenetics involves changes in gene expression (methylation, histone modification) without
DNA sequence changes. DNA sequence changes (A), chromosomal abnormalities (C), and mitochondrial
mutations (D) are genetic, not epigenetic.
Q10: Which evidence-based practice model emphasizes the integration of clinical expertise, patient
values, and best research evidence?
